To ask Her Majesty's Government how many (1) immunocompromised, or (2) immunosuppressed, people have received (a) antiviral, or (b) monoclonal, antibody treatments for COVID-19.

Information on the number of doses administered to immunocompromised people is not available in the format requested. These individuals are a priority for treatments, alongside those with other clinical conditions as determined by an independent advisory group.

The neutralising monoclonal antibody Ronapreve has been available to treat patients with COVID-19 in England since September 2021. As of 6 February 2022, 86 patients have been treated through COVID Medicines Delivery Units (CMDUs). The deployment of the neutralising monoclonal antibody sotrovimab began on 20 December 2021. As of 6 February 2022, 7,246 patients have been treated through CMDUs. The deployment of the oral antiviral molnupiravir began on 16 December 2021. As of 6 February 2022, 5,787 patients have been treated through CMDUs.

As of 16 January 2022, 4,962 patients have been treated with Ronapreve in hospitals; 457 patients have been treated with sotrovimab in hospitals; and 49,966 patients have been treated with Remdesivir in all settings. As of 8 February 2022, 7,868 people have been enrolled on the PANORAMIC national study, with half the participants receiving molnupiravir treatment.